ライフサイエンスコーパス: NG-nitro-L-arginine

1 medium supplemented with the arginine analog NG-nitro-L-arginine.

2 larly, NG-monomethyl-L-arginine 1 mmol/L and NG-nitro-L-arginine 10 micromol/L attenuated PSD by 57.5

3 intact male mouse aortic rings treated with NG-nitro-L-arginine, 17 beta-estradiol caused dose-depen

4 (C, Ringer solution), NOS-inhibited (10.0 mM NG-nitro-L-arginine), arginase-inhibited (5.0 mM (S)-(2-

5 arginine site of cNOS, as assessed from [3H]NG-nitro-L-arginine binding, nor did they potently effec

6 However, NO blockade with intracoronary NG-nitro-L-arginine blocked the enhanced coronary vasodi

7 , but not SNAP, were blocked by 10(-4) mol/L NG-nitro-L-arginine, consistent with both BK and CCh sti

8 synthase inhibitors, NG-methyl-L-arginine or NG-nitro-L-arginine in a dose-dependent manner.

9 venous infusion of the NO synthase inhibitor NG-nitro-L-arginine (L-NA, 13 mg/kg before the first occ

10 Administration of NG-nitro-L-arginine (L-NNA) abolished the increase in ca

11 The neutral nitric oxide synthase inhibitors NG-nitro-L-arginine (L-NNA) and N omega-monomethyl-L-arg

12 effect of a nitric oxide synthase inhibitor, NG-nitro-L-arginine (L-NNA) on free radical generation a

13 In this study, treatment with NG-nitro-L-arginine (L-NoArg), an arginine analog that i

14 lium or addition of a NO synthase inhibitor, NG-nitro-L-arginine (LNNA), in control arteries decrease

15 g(-1).min(-1) for 28 days) or treatment with NG-nitro-L-arginine methyl ester (1 mg/mL in drinking wa

16 4 pigs after inhibition of NO synthase with NG-nitro-L-arginine methyl ester (1 to 2 mg/kg IV) had r

17 (5 mumol/L), a cyclooxygenase inhibitor, or NG-nitro-L-arginine methyl ester (100 mumol/L), a nitric

18 he nonselective NO* synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (100-800 nmol) as well

19 NG-nitro-L-arginine methyl ester (an NO synthase inhibit

20 Addition of the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mg/ml) to t

21 0 mm Hg from baseline, nine animals received NG-nitro-L-arginine methyl ester (L-NAME) at 15 mg/kg to

22 of the rat mesentery with 50 micromol/liter NG-nitro-L-arginine methyl ester (L-NAME) caused a signi

23 NG-nitro-L-arginine methyl ester (L-NAME) constricted an

24 tric oxide (NO) generation with low doses of NG-nitro-L-arginine methyl ester (L-NAME) corrects the h

25 were treated with the NO synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) for 14 days pl

26 onimine (SIN-1) or the NO synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) in 12 control

27 of the arteries was coated with 1 mmol/L of NG-nitro-L-arginine methyl ester (L-NAME) in 22% (wt/vol

28 In Site B, NG-nitro-L-arginine methyl ester (L-NAME) infusion durin

29 on renal fibrosis, enalapril, enalapril plus NG-nitro-L-arginine methyl ester (L-NAME) or L-arginine

30 er the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME) or saline vehi

31 Molsidomine or NG-nitro-L-arginine methyl ester (L-NAME) or saline were

32 bited by the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) or the ATP-sen

33 Blockade of NOS activity with NG-nitro-L-arginine methyl ester (L-NAME) significantly

34 In contrast, NG-nitro-L-arginine methyl ester (L-NAME) treatment (250

35 anoid/NO protocol: (1) ketorolac (Keto), (2) NG-nitro-l-arginine methyl ester (L-NAME), (3) Keto + l-

36 ied hemoglobin known to scavenge NO, and (2) NG-nitro-L-arginine methyl ester (L-NAME), a competitive

37 RT activators was reduced in the presence of NG-nitro-L-arginine methyl ester (L-NAME), a general inh

38 uncal vagotomy (TV), hexamethonium (C6), and NG-nitro-L-arginine methyl ester (L-NAME), but not by va

39 administration of the general NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME), but not its d

40 ich a nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), is neuroprote

41 mps containing an inhibitor of nitric oxide, NG-nitro-L-arginine methyl ester (L-NAME), or a correspo

42 NG-nitro-L-arginine methyl ester (L-NAME)-sensitive non-

43 red with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME).

44 NG-nitro-L-arginine methyl ester (L-NAME, 300 microM), a

45 The NG-nitro-L-arginine methyl ester (L-NAME, a NOS inhibito

46 erebroventricular (i.c.v.) administration of NG-nitro-l-arginine methyl ester (L-NAME; 150 microg/5 m

47 the nitric oxide synthesis (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 25 micromol/kg

48 ally); a nonselective NO synthase inhibitor, Ng-nitro-L-arginine methyl ester (L-NAME; 30 mg/kg given

49 Concomitant administration of LPS + NG-nitro-L-arginine methyl ester (L-NAME; an NO synthesi

50 NG-monomethyl-L-arginine (L-NMMA; n = 6) or NG-nitro-L-arginine methyl ester (L-NAME; n = 8).

51 onovaleric acid and by NO synthase inhibitor NG-nitro-L-arginine methyl ester and NG-monomethyl-L-arg

52 s in nitrite, a response that was blocked by NG-nitro-L-arginine methyl ester and receptor-specific a

53 er saline or treatment with a combination of NG-nitro-l-arginine methyl ester and sodium nitroprussid

54 e treated with the nonspecific NOS inhibitor NG-nitro-L-arginine methyl ester and the NOS1-specific i

55 tory effect of erythromycin was decreased by NG-nitro-L-arginine methyl ester and the vasoactive inte

56 Local application of 10(-4) mol/L NG-nitro-L-arginine methyl ester caused about the same r

57 O synthase inhibitors N-nitro-L-arginine and NG-nitro-L-arginine methyl ester did not modify either b

58 a greater percentage decrease in response to NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME)

59 lated fibres with the NO synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride (L-NAME)

60 NG-nitro-L-arginine methyl ester increased mean aortic p

61 The inhibitory effect of NG-nitro-L-arginine methyl ester on the response to brad

62 urthermore, treatment of wild-type mice with NG-nitro-L-arginine methyl ester or loperamide prevented

63 abolished by the NO biosynthesis inhibitor (NG-nitro-L-arginine methyl ester) in the proximal and th

64 before and after systemic administration of NG-nitro-L-arginine methyl ester, an arginine analogue k

65 The administration of NG-nitro-L-arginine methyl ester, an inhibitor of NOS ac

66 A nitric oxide synthesis inhibitor, NG-nitro-l-arginine methyl ester, did not reverse the in

67 ated NO* with the competitive NOS inhibitor, NG-nitro-l-arginine methyl ester, in cells grown in l-ar

68 administration of an NO synthase inhibitor, NG-nitro-L-arginine methyl ester, significantly inhibite

69 THF reversed eNOS uncoupling, as assessed by NG-nitro-l-arginine methyl ester-inhibitable superoxide

70 5 x 10(-8) mol/L) caused a tetrodotoxin- or NG-nitro-L-arginine methyl ester-insensitive inhibition

71 ented by the nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester.

72 microvascular endothelium with 50 micromol/L NG-nitro-L-arginine methyl ester.

73 testinal polypeptide antagonist, apamin, and NG-nitro-L-arginine methyl ester.

74 e inducible nitric oxide synthase inhibitors Ng-nitro-L-arginine-methyl ester (1.5 mmol/L) and aminog

75 g) of the nonselective NO synthase inhibitor NG-nitro-L-arginine-methyl ester (L-NAME) were administe

76 odel, mice received daily i.p. injections of NG-nitro-L-arginine-methyl ester (L-NAME; 8 mg/kg) durin

77 In RAW cells, Ng-nitro-L-arginine-methyl ester and AG block IFNgamma/L

78 Treatment of nNOS with NG-nitro-L-arginine or 7-nitroindazole led to stabilizat

79 ence of the nitric oxide synthase inhibitor, NG-nitro-L-arginine or the endothelin B receptor antagon

80 Studies with NG-nitro-L-arginine, which does not distinguish among NO